Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 2:10:529.
doi: 10.1186/1471-2458-10-529.

Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

Jürgen Scholze  1 , Eduardo Alegria, Claudio Ferri, Sue Langham, Warren Stevens, David Jeffries, Kerstin Uhl-Hochgraeber
Affiliations

Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

Jürgen Scholze et al. BMC Public Health. .

Abstract

Background: The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the epidemiological and economic burden to the health service of metabolic syndrome in patients with hypertension in three European countries in 2008 and 2020.

Methods: An age, sex and risk group structured prevalence based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define metabolic syndrome. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy.

Results: The prevalence of hypertension with metabolic syndrome in the general population of Germany, Spain and Italy was 36%, 11% and 10% respectively. In subjects with hypertension 61%, 22% and 21% also had metabolic syndrome. Incident cardiovascular events and attributable mortality were around two fold higher in subjects with metabolic syndrome and prevalence of type 2 diabetes was around six-fold higher. The economic burden to the health service of metabolic syndrome in patients with hypertension was been estimated at €24,427, €1,900 and €4,877 million in Germany, Spain and Italy and forecast to rise by 59%, 179% and 157% respectively by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with metabolic syndrome compared to those without and rose incrementally with the additional number of metabolic syndrome components present.

Conclusion: The presence of metabolic syndrome in patients with hypertension significantly inflates economic burden and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of metabolic syndrome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the burden of illness model.
Figure 2
Figure 2
Proportion of the hypertensive population > 20 years within each risk group; 2008-2020.
Figure 3
Figure 3
Prevalence of individual components of MetS in patients with hypertension; 2008 and 2020.
Figure 4
Figure 4
Proportion of drug, physician, cardiovascular and type 2 diabetes costs to total annual costs for patients with hypertension and MetS; 2008.
Figure 5
Figure 5
Mean annual costs (Euros) per hypertensive patient according to the number of components of MetS; 2008.
See this image and copyright information in PMC

References

    1. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518. doi: 10.1016/S0140-6736(08)60655-8. - DOI - PubMed
    1. Groves T. Pandemic obesity in Europe. BMJ. 2006;333 1081-1com. - PMC - PubMed
    1. Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. Circulation. 1998;98:1472–1476. - PubMed
    1. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S. et al.Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens. 2009;27:441–451. doi: 10.1097/HJH.0b013e32831e13e5. - DOI - PubMed
    1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–1778. doi: 10.2337/diacare.28.7.1769. - DOI - PubMed

Publication types